Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC

Chengxiang Yi*,1,2, Yayi He*,3, Haoran Xia*,1, Helin Zhang4, Peng Zhang1 1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China; 2Tongji University School of Medicine, Tongji University, Shanghai 200433, People’s Republic of China; 3Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China; 4Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang City, People’s Republic of China*These authors contributed equally to this workCorrespondence: Peng ZhangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, No. 507, Zhengmin Road, Yangpu District, Shanghai, People’s Republic of ChinaTel +86 1 351 218 5932Email zhangpeng1121@tongji.edu.cnHelin ZhangDepartment of Thoracic Surgery, Hebei The Second Hospital of Hebei Medical University, No. 53, Huaxi Road, Xinhua District, Shijiazhuang City, People’s Republic of ChinaEmail zhanghelin@hotmail.comAbstract: Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on NSCLC are still being explored. In this review, we summarized the research progress and outline the issues need to be solved on adjuvant and neoadjuvant immunotherapies in NSCLC.Keywords: adjuvant immunotherapies, neoadjuvant immunotherapies, immune checkpoint inhibitor, non-small-cell lung cancer, biomarker, liquid biopsy